Drug Type Small molecule drug |
Synonyms PBI 4425, PBI4425 |
Target |
Action antagonists, agonists |
Mechanism G-protein coupled receptor 84 antagonists, GPR40 agonists(Free fatty acid receptor 1 agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pulmonary Fibrosis | Preclinical | Canada | 12 May 2020 | |
Acute Lung Injury | Preclinical | Canada | 02 May 2020 | |
Scleroderma | Preclinical | Canada | 31 Dec 2017 | |
Diabetic Nephropathies | Preclinical | Canada | 14 May 2016 |